Wu Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;S1473-3099(20)30987-7. doi:10.1016/S1473-3099(20)30987-7
Patki M, et al. Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment. Int J Pharm. 2021;120329. doi:10.1016/j.ijpharm.2021.120329
現行のレムデシビルは点滴静注
レムデシビルの自己注射可能な徐放性皮下注射製剤SelfExRemを開発
通院を最小限に抑える、対面接触を減らす、投与頻度を減らす、などの利点
Luo Z, et al. The preventive effect of Xuebijing injection against Cytokine Storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med. 2021;101305. doi:10.1016/j.eujim.2021.101305
Hirotsu Y, et al. Prospective Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using the LUMIPULSE SARS-CoV-2 Antigen Test: Comparison with RT-qPCR. Int J Infect Dis. 2021;S1201-9712(21)00090-4. doi:10.1016/j.ijid.2021.02.005
Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;10.1038/s41586-021-03291-y. doi:10.1038/s41586-021-03291-y
Lin JW, et al. Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon response. Cell Host Microbe. 2021;S1931-3128(21)00045-7. doi:10.1016/j.chom.2021.01.015
Nsp1遺伝子のコード領域に欠失(Δ500-532)をもつ変異株
世界37カ国で発見、シーケンスされたサンプルの20%以上で見つかる
IFN-β応答を誘導する活性が低い→血清IFN-βレベルが低い
Takeda Y, et al. The SARS-CoV-2-Inactivating Activity of Hydroxytyrosol-Rich Aqueous Olive Pulp Extract (HIDROX®) and Its Use as a Virucidal Cream for Topical Application. Viruses. 2021;13(2):232. doi:10.3390/v13020232 帯広畜産大